Related Experiment Videos
Why do we need randomized and epidemiological studies on cardiovascular disease? Evidence-based cardiology VII
A Avezum1, J M Rossi Neto, L Piegas
1Instituto Dante Pazzanese de Cardiologia, São Paulo.
Insights
Randomized clinical studies and epidemiological research have improved cardiovascular disease (CVD) treatment and prevention. Evidence-based medicine adoption is crucial for reducing CVD deaths globally, especially in developing nations.
Area of Science:
- Cardiology and Epidemiology
- Public Health and Preventative Medicine
Background:
- Cardiovascular disease (CVD) causes 12 million deaths annually, with a rising trend in developing countries.
- An epidemiological transition in developing nations necessitates global CVD prevention strategies.
- Evidence-based medicine (EBM) in treating coronary artery disease (CAD) and heart failure (HF) can save lives.
Purpose of the Study:
- To highlight the impact of randomized clinical studies and epidemiological research on cardiology.
- To emphasize the importance of EBM in managing cardiovascular diseases.
- To discuss the growing burden of CVD in developing countries and the need for prevention.
Main Methods:
- Review of randomized clinical studies and epidemiological research.
- Analysis of global CVD mortality and morbidity trends.
- Assessment of the role of risk factor identification and management.
Main Results:
- Randomized studies have significantly improved cardiological practice and clinical outcomes.
- EBM implementation can prevent hundreds of thousands of CVD deaths annually.
- Brazil has seen scientific growth and evidence-based practice consolidation through multi-center studies.
Conclusions:
- Robust clinical studies and EBM are essential for effective cardiovascular disease management.
- Addressing the CVD epidemic in developing countries requires global prevention strategies.
- Collaborative research enhances scientific understanding and clinical practice in cardiology.
Abstract:
Over the last two decades the results of randomized clinical studies, which are powerful aids for correctly assessing therapeutical strategies, have consolidated cardiological practice. In addition, scientifically interesting hypotheses have been generated through the results of epidemiological studies. Properly conducted randomized studies without systematic errors and with statistical power adequate for demonstrating moderate and reasonable benefits in relevant clinical outcomes have provided reliable and strong results altering clinical practice, thus providing adequate treatment for patients with cardiovascular disease (CVD). The dissemination and use of evidence-based medicine in treating coronary artery disease (CAD), heart failure (HF), and in prevention will prevent hundreds of thousands of deaths annually in developed and developing countries. CVD is responsible for approximately 12 million deaths annually throughout the world, and approximately 60% of these deaths occur in developing countries. During recent years, an increase in mortality and morbidity rates due to CVD has occurred in developing countries. This increase is an indication that an epidemiological (demographic, economical, and health-related) transition is taking place in developing countries and this transition implies a global epidemic of CVD, which will require wide-ranging and globally effective strategies for prevention. The identification of conventional and emerging risk factors for CVD, as well as their management in high-risk individuals, has contributed to the decrease in the mortality rate due to CVD. Through a national collaboration, several multi-center and multinational randomized and epidemiological studies have been carried out throughout Brazil, thus contributing not only to a generalized scientific growth in different Brazilian hospitals but also to the consolidation of an increasingly evidence-based clinical practice.